All Cancers - One Solution
SMART-Phage™ for Truly Tumor-Specific Antibody Discovery
All cancers share one feature:
Tn/STn antigens, abundant in tumors - absent in healthy cells
Healthy tissue
Tumor tissue
Combotopes' proprietary SMART-Phage™ Antibody Discovery Platform
Tumor specificity
High affinity
Flexibility
Novel and revisited cancer targets
ADC, BsAb, BiTE, RIT, CART
Untouched IP space
We deliver:
EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN
〰️
EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN 〰️
We offer an attractive win-win partnership business model
Upfront, and milestone payments tied to development and regulatory achievements
Royalties on product sales
Crystal structure revealing how Combotope antibodies specifically binds cancer-specific Tn-glycoprotein epitopes
Leadership
-
Dr. Klas Ola Blixt
CO-FOUNDER, INVENTOR, & CEO
Ola invented the SMART-Phage technology and is an expert in aberrant glycosylation and development of cancer-specific antibodies. With 20+ years in chemical biology and antibodies, he has an H-index of 50, multiple patents, and 15+ years of management experience.
-
Dr. Søren Nyboe Jakobsen
CO-FOUNDER, CxO
Søren is an inventor of patents in molecular display and immune cell detection. He founded Tetramer Shop, acquired by 10x Genomics, and has driven innovation at Novo Nordisk, Nuevolution, Immudex, and 10x Genomics, with strong experience building and scaling biotech startups.
Combotope Therapeutics ApS
Ole Maaløes Vej 3
DK-2200 Copenhagen N
Denmark
Contact:
olablixt@combotope.com
Company registration (CVR) no. 44308266
